ExeVir

Exevir Bio is a biotech company developing efficacious heavy chain-only antibodies to prevent and treat infectious diseases and make a difference in pandemic preparedness. The technology platform of ExeVir uses humanized camelid heavy chain-only antibody fragments (VHH) fused to a human IgG Fc to create new therapeutic compounds. ExeVir is building a strong pipeline of antibody therapies with an initial focus on COVID-19 and dengue. Compared to conventional monoclonal antibodies, the modular VHH building blocks provide a unique combinatory flexibility. In addition, the design of multi-specific constructs is substantially simplified. VHHs have the potential to access unique and occluded epitopes that are often highly conserved and more difficult, if not impossible, to access for conventional monoclonals. ExeVir has gained extensive experience in the discovery, development and production of mono-specific and multi-specific VHH-Fc constructs, which are very stable, easy to produce and cost-effective. Our lead compound XVR013m is a variant-proof and broad –spectrum long-acting antibody targeting a highly conserved epitope in the S2 subunit of the Spike to protect and treat immunocompromised and elderly. The company is backed up by series A financing and has obtained non-dilutive funding from VLAIO and Horizon. The company was created in 2020 and has its headquarters in Ghent, Belgium.